Initiating Jardiance in Patients with Type 2 Diabetes and A1c of 9.5%

Initial Treatment Strategy

The American Diabetes Association recommends dual therapy for patients with A1c ≥1.5% above the glycemic target, which applies to patients with A1c 9.5%, with metformin plus a second agent as the preferred initial approach 1, 3
For patients with established atherosclerotic cardiovascular disease (ASCVD), SGLT2 inhibitors like Jardiance are recommended as part of the antihyperglycemic regimen regardless of A1c level, with a strength of evidence based on high-quality clinical trials 4, 5, 6
The American College of Cardiology recommends SGLT2 inhibitors as the preferred class for patients with heart failure or at high risk for heart failure, due to their demonstrated cardiovascular benefits 4, 5, 6

SGLT2 inhibitors provide both glycemic control and renal protection for patients with chronic kidney disease, with a moderate to high strength of evidence 4, 5
Jardiance demonstrates cardiovascular mortality reduction in patients with established ASCVD, with a high strength of evidence based on large clinical trials 6
The American College of Cardiology recommends Jardiance for heart failure hospitalization reduction, particularly for patients with or at risk for heart failure, based on high-quality evidence 6

The American Diabetes Association recommends starting metformin at 500-850 mg daily, titrating to 2000 mg daily over 2-4 weeks, and adding Jardiance 10 mg daily immediately, with a strength of evidence based on clinical guidelines 1, 6
For patients with cardiovascular or renal comorbidities, Jardiance 10 mg is sufficient for organ protection and does not require uptitration for CV benefit, based on moderate to high strength of evidence 6

The American Diabetes Association recommends reassessing A1c in 3 months to evaluate treatment effectiveness, with a strength of evidence based on clinical guidelines 1
Monitoring for genitourinary infections, renal function, volume depletion, and diabetic ketoacidosis risk is recommended, with a moderate strength of evidence based on clinical experience 1, 4, 5

Delaying dual therapy by trying metformin monotherapy first at A1c 9.5% prolongs exposure to severe hyperglycemia and increases complication risk, with a high strength of evidence based on clinical trials 1, 2, 8
Not using Jardiance as part of a dual therapy regimen in newly diagnosed patients with ASCVD, heart failure, or chronic kidney disease may miss opportunities for cardiovascular and renal protection, with a moderate to high strength of evidence based on clinical guidelines 4, 5, 6